“bluebird bio is a pioneer in the field of lentiviral vector-based cell
and gene therapy, and our partnerships and licensing agreements have
been crucial to our success since our early days. We have continued to
build upon our intellectual property, applying the incredible potential
of lentiviral vectors to both our ongoing clinical gene therapy and
immuno-oncology programs,” said
Under the terms of the agreement with
Financial terms of the agreement include an upfront payment to bluebird as well as milestone and royalty payments.
About bluebird bio, Inc.
With its lentiviral-based gene therapies, T cell immunotherapy expertise and gene editing capabilities, bluebird bio has built an integrated product platform with broad potential application to severe genetic diseases and cancer. bluebird bio’s gene therapy clinical programs include its Lenti-D™ product candidate, currently in a Phase 2/3 study, called the Starbeam Study, for the treatment of cerebral adrenoleukodystrophy, and its LentiGlobin™ product candidate, currently in four clinical studies for the treatment of transfusion-dependent β-thalassemia, and severe sickle cell disease. bluebird bio’s oncology pipeline is built upon the company’s leadership in lentiviral gene delivery and T cell engineering, with a focus on developing novel T cell-based immunotherapies, including chimeric antigen receptor (CAR T) and T cell receptor (TCR) therapies. bluebird bio’s lead oncology program, bb2121, is an anti-BCMA CAR T program partnered with Celgene. bb2121 is currently being studied in a Phase 1 trial for the treatment of relapsed/refractory multiple myeloma. bluebird bio also has discovery research programs utilizing megaTAL/homing endonuclease gene editing technologies with the potential for use across the company’s pipeline.
bluebird bio has operations in Cambridge,
This release contains “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995, including
statements regarding the Company’s license agreements with third parties
and our licensee’s product candidates, as well as the advancement of,
and anticipated development and regulatory milestones and plans related
to the Company’s product candidates and clinical studies. Any
forward-looking statements are based on management’s current
expectations of future events and are subject to a number of risks and
uncertainties that could cause actual results to differ materially and
adversely from those set forth in or implied by such forward-looking
statements. These risks and uncertainties include, but are not limited
to, risks that the product candidates of our licensees are not
successfully developed, approved or commercialized, risks that the
preliminary results from our clinical trials will not continue or be
repeated in our ongoing clinical trials, the risk of cessation or delay
of any of the ongoing or planned clinical studies and/or our development
of our product candidates, risks that the current or planned clinical
trials of the LentiGlobin drug product will be insufficient to support
regulatory submissions or marketing approval in the
Source: bluebird bio, Inc.